(AOF) – Following the announcement of the proposed acquisition of Biocorp by Novo Nordisk (a leading global company in the field of health care, Biocorp announces, following the obtaining of the usual regulatory authorizations, the realization today of the off-market acquisition by Novo Nordisk from Bio Jag, main shareholder of Biocorp (as well as certain minority shareholders, including Nyenburgh, Greenstock and Vatel Capital) of a total of 2,838,669 shares representing 64.3% of the capital and 64.09% of the voting rights of Biocorp for a price of 35 euros per share.
The outstanding convertible bonds issued by Biocorp have been fully redeemed in cash by Biocorp as of the date hereof in connection with the completion of the acquisition of the Control Block.
As a result of this achievement, the composition of Biocorp’s Board of Directors has been modified to take into account the new configuration of its shareholding. Following the resignation of Messrs. Jacques Gardette and Julien Gardette from their directorships, Biocorp’s Board of Directors is made up of five members in total, namely: Ms. Marianne Ølholm and Messrs. Peter Bøggild, Eric Dessertenne, Jean-Yves Berthon and Stephane Legastelois.
Ms. Marianne Ølholm and Mr. Peter Bøggild were co-opted to replace Messrs. Jacques Gardette and Julien Gardette. These cooptations, which took effect today, will be subject to ratification by the next ordinary general meeting of Biocorp shareholders.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
